, suggesting that the putative propeptide might contribute to the conformational stability of the active site cleft and surrounding regions.
INTRODUCTION
Mycobacterium tuberculosis is one of the most infectious pathogenic bacteria, and has caused huge numbers of fatalities in humans for millennia. Mycobacteria are able to evade host immune responses by delivering virulence molecules into host cells, and they have developed a specialized secretion system, the type VII secretion system (T7SS), to excrete virulence factors across their highly impermeable cell envelope (Stanley et al., 2003; Abdallah et al., 2007; DiGiuseppe Champion and Cox, 2007) . ESX-1 secretion system is the intensely studied T7SS in M. tuberculosis. ESX-1 secretion is required for early replication and full virulence in macrophages, and has multiple effects on host cells (Brodin et al., 2004; McLaughlin et al., 2007; Raghavan et al., 2008) . Studies in M. tuberculosis and related mycobacteria have identifi ed components necessary for ESX-1 export activity, including predicted ATPases (EccA1 and EccCb1) and several membrane proteins (MycP1, EccB1, EccCa1, EccD1, and EccE1) (Stanley et al., 2003; Ligon et al., 2012) . In addition to conventional substrates (EAST-6 and CFP-10), several other substrates of ESX-1 export system were also identifi ed: EspA, EspB, EspC, and EspR (Fortune et al., 2005; McLaughlin et al., 2007; Xu et al., 2007) . It was also known that secretion of all substrates was mutually dependent with components of the T7SS (Fortune et al., 2005) .
MycP1 is an essential component of the ESX-1 T7SS, and gene deletion abolished secretion in the complex lacking MycP1 (Ohol et al., 2010) . At the same time, introduction of catalytically inactive MycP1 constructs (protease activity abolished by mutation of the catalytic residues) into mycobacteria enhanced ESX1-mediated secretion (Ohol et al., 2010) . This counter-intuitive fi nding led to the proposal of a dual role for MycP1 in the regulation of ESX-1 secretion (Ohol et al., 2010) .
Primary sequence analysis identified MycP1 as member of the subtilase class of serine proteases, with an additional N-terminal Sec signal sequence and a C-terminal transmembrane domain that anchors the protein to the inner membrane, leaving the catalytic peptidase domain in the extra-cytoplasmic space (Brown et al., 2000; Dave et al., 2002) . Classical subtilase family proteases have a propeptide and an Asp-His-Ser catalytic triad. The propeptide may facilitate the folding of the protease domain by acting as an inter-molecular chaperone (Zhu et al., 1989) . After self-cleavage during the maturation process, the severed propeptide can act as a potent inhibitor (Zhu et al., 1989; , and removal or degradation of the propeptide may be required to generate the active protease. Several crystal structures of subtilisins have been obtained for inactive auto-processed (propeptide-subtilisin complex) (Gallagher et al., 1995; Jain et al., 1998; Tanaka et al., 2007) , matured (Bott et al., 1988; Tanaka et al., 2007) , and unautoprocessed forms (Tanaka et al., 2007) . These structures showed that the propeptide was separated from the protease domain but remained locating in the substrate entrance to the active site (Gallagher et al., 1995; Jain et al., 1998) . Interactions between residues in the propeptide and protease domains therefore play an essential role in manipulating the catalytic activity of subtilases.
Previous studies indicated that the secreted protein EspB, a substrate of MycP1, mediates a feedback mechanism in the maintenance of virulence in mycobacteria (Ohol et al., 2010) . EspB was cleaved at two different sites by activated MycP1 protease (Ohol et al., 2010; Solomonson et al., 2013) . The EspB assay can be used to study the maturation process of the MycP1 protein, including propeptide cleavage and its role in regulating protease activity.
To answer the above questions, we have determined the crystal structures of MycP1 with (MycP1 ) and without (MycP1 ) the putative propeptide. The structures revealed that the putative propeptide wraps around the protease domain in a way that is very different from classical subtilases. The overall similarity of the protease domains in the two structures was high, indicating minimal conformational interference from the propeptide. EspB cleavage assays verifi ed that there was no direct inhibition of proteolytic activity by the propeptide. Molecular dynamic simulations suggested a possible role of the putative propeptide in maintaining the conformational stability of regions guarding entrance to the catalytic site of MycP1.
RESULTS AND DISCUSSION
Crystal structure of MycP1
24-422
MycP1 from M. smegmatis shares about 80% sequence identity to its homolog in M. tuberculosis (Fig. S1 ), making it a suitable model for studying mycosins of pathogenic mycobacteria. Previous studies have indicated that MycP1 from M. smegmatis contained a Sec secretion signal sequence (1-23) and a transmembrane helix (423-446) (Ohol et al., 2010) (Fig. S2A) (Fig. 1) . The overall structure of MycP1 24-422 includes a central parallel β-sheet sandwiched between α-helices, plus several extended loops (Figs. 2A and S3) . A total of four groups of β-sheets (a highly twisted sixstranded parallel β-sheet, two two-stranded and one threestranded anti-parallel β-sheets) and ten α-helices are visible. A β-α-β unit consisting of a central six-stranded parallel β-sheet (β3, β2, β5, β7, β9, and β10) with fi ve α-helices (α3, α4, α5, α8, and α9) packed on both sides of the central sheet formed the core of the protease domain. Recently, the crystal structure of Mycosin-1 (MycP1 ) was reported by Solomonson, M. et al. (2013) (Smith et al., 1999) , subtilisin BL (Goddette et al., 1992) , and subtilisin Carlsberg (Cianci et al., 2010), with RMSD values of 0.884, 0.940, and 0.829 Å over 173, 187, and 168 Cα atoms, respectively (Fig. 2B ). However, it was found the predicted MycP1 catalytic cleft was unusually large in comparison to typical subtilisin-like enzymes of known structure (Solomonson et al., 2013) . This is in part due to a 22-residue insertion after the β3 substrate-binding strand (Arg154-Thr175). Further, the β12/β13 strand is extended (Pro322-Pro327) to form a second mycosin-specific insertion that sits over the cleft to form a "lid" over the catalytic site (Fig. 3A) . Sequence alignment of MycP1 with other subtilases identified conserved residues involved in catalysis, including the catalytic triad Asp-His-Ser (Fig. 1) . It was previously predicted that the residues involved in hydrolysis are Asp90, His121, and Ser332 in M. tuberculosis MycP1 (Ohol et al., 2010) , corresponding to Asp92, His123, and Ser334 in the M. smegmatis enzyme (Figs. S1 and S2). In the MycP1 structure, the catalytic triad residues are located at the edge of the central β-sheet, with Asp92 being the last residue of strand β2 and His123 and Ser334 positioned at the beginning of α3 and α8, respectively ( Fig. 2A) . The spatial arrangement of the catalytic triad in MycP1 aligned well with those in subtilisin Carlsberg, subtilisin & BL, and Bacillus AK.1 (Fig. 2C ). The combined sequence and structural homology strongly indicated that MycP1 24-422 is a member of the subtilisin serine protease family.
The putative propeptide wrapped around the protease domain of MycP1
With MycP1 predicted to be a member of the subtilase family, the N-terminal segment (residues 21-63) of the M. tuberculosis enzyme was assumed to be a putative propeptide (Ohol et al., 2010 ) that would inhibit the activity of protease, but activate the protease function after its self-cleavage and degradation. The putative propeptide of the M. smegmatis protein (Ile24-Arg65; Fig. S2A ) was observed to adopt a disordered structure in the crystal structure of MycP1 24-422 ( Fig. 3A) . In the middle of the disordered region, a short β-strand (β1; residues T45, E46, and Q47) was observed to form an antiparallel β-sheet with β4 of the core protease domain (Fig. 3A) . In addition, a disulfi de bond connecting the putative propeptide and core protease domain was found between Cys51 and Cys120 (Fig. 3A) . 
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The structure of the putative propeptide in MycP1 is significantly different from propeptide structures of typical subtilases such as Tk-subtilisin, in which the propeptide forms a discrete globular domain comprising a four-stranded antiparallel The protein sequence was aligned with three subtilisin-like protease members (AK.1 serine protease, subtilisin BL, and subtilisin Carlsberg). The conserved catalytic triad residues (Asp, His, and Ser) are marked with blue stars. The sequence alignment was generated using ClustalW2 (Larkin et al., 2007) and decorated using ESPript (Gouet et al., 1999) . (Fig. 3B ) (Tanaka et al., 2007) . In the Tk-subtilisin structure, the propeptide domain blocked the entrance of the protease domain active site (Fig. 3B) . During the maturation process of classical subtilases, cleavage of the propeptide not only exposes the serine protease active site, but also abolishes interactions between the propeptide and the core protease domain, leading to conformational changes of the protease domains (Fu et al., 2000; Tanaka et al., 2007) . Therefore, the propeptide was considered as a potential inhibitor, and subtilases are only active after cleavage and degradation of the propeptide. However, in this study, the putative propeptide region (Ile24-Arg65) of MycP1 was not observed to form a standalone globular structure, but instead wraps around the core protease domain in a largely unstructured mode, with specific antiparellel β-sheet and disulfide bridge interactions (Fig. 3A) . In conventional subtilases, the propeptide was also reported to act as an intra-molecular chaperone, aiding the correct folding of the core protease domain (Zhu et al., 1989; Shinde and Inouye, 1995; Fu et al., 2000) . However, in this study, cleavage of the propeptide from MycP1 24-422 did not infl uence the structure of the core domain. Crystal structure of MycP1 , the MycP1 protein with its propeptide truncated, was determined to a resolution of 2.25 Å with an R and R free of 16.60% and 22.18%, respectively. Superposition of the Cα atoms) revealed almost identical core protease domains (Fig. 4A ). This finding does not support an intra-molecular chaperone function for the propeptide of MycP1, unlike that of Tk-subtilisin (Tanaka et al., 2007) . Both the unstructured and intimately wrapped features of the MycP1 propeptide were in stark contrast to propeptide structures of classical subtilases, and suggest that the N-terminal segment (Ile24-Arg65) of MycP1 does not function as a conventional propeptide in the regulation and maturation of MycP1. To verify this hypothesis, functional assays were conducted to analyze the potential in- 
EspB cleavage assay
In mycobacteria, EspB is an important substrate of the ESX-1 T7SS. Previous studies reported that the catalytically inactive MycP1 mutant did not cleave EspB, while active MycP1 processed EspB effi ciently (Ohol et al., 2010) . Two cleavage sites for MycP1 in EspB were identifi ed, although it was not clear whether the active MycP1 contained the putative propeptide or not (Ohol et al., 2010) . To verify the functional role of the putative propeptide of MycP1, the EspB cleavage assay was conducted using MycP1 24-422 and MycP1 . Following the previously established EspB cleavage protocol (Ohol et al., 2010; Solomonson et al., 2013) 63-422 at a molar ratio of 5:1 (Fig. 4B) , and the proteolytic activity was analyzed using SDS-PAGE. The catalytically inactive MycP1-S334A mutant was used as negative control. After overnight incubation with MycP1 at 37°C, EspB migrated at a lower molecular weight (~45 kDa) compared with the intact EspB (~60 kDa; Fig. 4B ). An additional lower molecular weight band at ~14 kDa corresponding to a truncated EspB fragment was observed for EspB cleavage using both MycP1 24-422 and MycP1 63-422 (Fig. 4B) . The truncated bands
were not observed when EspB was treated with the proteolytically inactive mutants MycP1 -S334A and MycP1 -S334A (Fig. 4B) . The observed protease activity of both MycP1 and MycP1 63-422 strongly indicated that the putative propeptide did not inhibit the protease activity. In a prolonged assay under the same conditions, EspB cleavage by MycP1 was found to be more efficient than MycP1 63-422 (Fig. 4C) .
Notably, MycP1 24-422 cleaved more than 90% of EspB after a 24 h incubation, while MycP1 63-422 cleaved about 50% (Fig. 4C ).
This observation strongly indicated the non-inhibitory effect of the putative propeptide to MycP1 protease, but mechanism of higher cleavage effi ciency of MycP1 with the presence of the propeptide region is interesting and should be explored in the future using other methods.
Flexibility analysis of MycP1 24-422 or MycP1

63-422
Following observation of similar structures for MycP1 with or without the propeptide, and establishing the non-inhibitory nature, the possible role of the propeptide was investigated using 15 ns molecular dynamics simulations with the crystal structures of MycP1 24-422 and MycP1 63-422 determined in this study. The RMSD for all backbone Cα atoms as a function of simulation time was calculated (Fig. S4A) . The RMSD values remained at 1.2 Å for MycP1 24-422 and 1.7 Å for MycP1 after 320 ps, demonstrating the stable conformations of these structures within the 15 ns simulations. Structure calculations were analyzed using the B-factors from the MD trajectory, and a strong correlation was observed with the experimental B-factors from the crystallographic data for MycP1 (Fig. S4B) and MycP1 (Fig. S4C) , indicating a robust MD simulation for both structures. The structural fl exibility of MycP1 24-422 and MycP1 63-422 was assessed using the root mean square fl uctuation (RMSF) of Cα atoms after the entire MD calculations. The RMSF for residues in fi ve regions (R1, residues 155-180; R2, 205-220; R3, 238-265; R4, 315-330; R5, 368-377) in the MycP1 63-422 MD simulation was observed to be generally higher than those of the corresponding MycP1 24-422 regions (Fig. 5A ). These fi ve regions were mapped to the MycP1 structure. The R1-R4 regions were found to be in close proximity to the putative propeptide region and also surround the entrance to the catalytic site of the protease, while the R5 region was observed to be close to R3 (Fig. 5B) . The more rigid conformation of MycP1 may be due to the stabilizing interactions between the putative propeptide and residues in the R1-R4 regions of the protease domain. The higher stability of MycP1 24-422 was consistent with the protease assay, in which higher protease effi ciency was also observed for MycP1 (Fig. 4C) . In combination, the EspB cleavage effi ciency data and molecular dynamics fl exibility analysis suggest the putative propeptide stabilizes the conformation of the MycP1 protease domain. Classical subtilases have been shown to use calcium ions and disulfi de bonds as two strategies for stabilizing their catalytic domains (Siezen and Leunissen, 1997) . Since no Ca 2+ ions or appropriate chelating amino acid residues were present in the MycP1 structure, calcium ions were not utilized by MycP1 (Solomonson et al., 2013) . Alternatively, two disulfi de bonds (Cys51-Cys120 and Cys206-Cys244) were observed in the MycP1 24-422 structure, which may be the only possible stabilization strategy used by MycP1. Disruption of the first disulfide bond through truncation of the putative propeptide region could significantly reduce the overall stability of the protein.
Together with the antiparallel β-sheet comprised of β1 (Thr45-Gln47) and β4, the disulfi de bridges and the rest of the putative propeptide appear to contribute to the stability of the protease domain. In a recent report, similar results were observed on the structure and function of MycP1 24-407 (Solomonson et al., 2013) .
However, Solomonson, M. et al. only described the structure of MycP1 . They have tried to over-express the truncated construct without the putative propeptide, but failed in not only structural studies, but also related functional EspB cleavage studies. Structural study of MycP1 63-422 reported here strongly indicated the majority of the putative propeptide is not required for folding. The reduced protease activity of MycP1 63-422 suggested that the N-terminal sequence does not serve as a typical inhibitory propeptide. In summary, structural and biochemical studies demonstrated that the putative propeptide of MycP1 neither serves as an intramolecular chaperone, nor as an inhibitor of proteolytic activity. Rather, truncation of the propeptide reduced protease effi ciency, and impaired the stability of the protease domain. Together, the results in this study indicate that the N-terminal sequence of MycP1 (Ile24-Arg65) does not serve as a typical inhibitory propeptide, but instead enhance the stability of the protease domain.
MATERIALS AND METHODS
Cloning, expression, and purifi cation of MycP1
The DNA sequence encoding M. smegmatis MycP1 24-422 (including the propeptide and the core protease domain, Fig. S2A ) was synthesized with codon optimization for E. coli (Sangon, Shanghai) and inserted into the pET21b vector (Novagen, CA) to include a C-terminal hexahistidine tag. The DNA sequence encoding MycP1 63-422 was amplifi ed using PCR and inserted into the pET-22b vector (Novagen, CA) to include an N-terminal hexahistidine tag. The constructs were transformed into E. coli BL21 (DE3) (Stratagene) for protein expression. Cells were grown in M9 medium at 37°C until OD 600 reached 0.8, then protein production was induced using 0.5 mmol/L IPTG (12 h at 25°C for MycP1 ; 48 h at 12°C for MycP1 ). MycP1 proteins were purifi ed by affi nity chromatography using a Ni-NTA column (Qiagen) followed by size-exclusion chromatography using a HiLoad 16/60 Superdex 200 column (GE Healthcare). The purified proteins were analyzed using SDS-PAGE.
Crystallization, data collection, and structure determination Crystals were harvested and soaked in a cryo-protectant solution consisting of the crystallization condition supplemented with 20% (v/v) glycerol for several seconds, and then fl ash-cooled in liquid nitrogen. X-ray diffraction data were collected on beamline BL17U at the Shanghai Synchrotron Radiation Facility (SSRF). Data were processed using HKL-2000 (Otwinowski and Minor, 1997) .
The structure of MycP1 24-422 was determined using the singlewavelength anomalous dispersion (SAD) method (Hendrickson, 1991) . The SeMet sites were located and the initial phases were calculated using the Phenix software package (Adams et al., 2002) . Residues in one asymmetric unit were automatically built using the Autobuild program. After tracing the initial model manually using the COOT program (Emsley and Cowtan, 2004) , the model was refi ned against the native data using REFMAC5 (Vagin et al., 2004) , then rebuilt interactively using the σ A -weighted electron density maps with coeffi cients 2mF o − DF c and mF o -DF c using COOT (Emsley and Cowtan, 2004) . Using the determined MycP1 24-422 structure as a search model, the structure of MycP1 63-422 was solved by molecular replacement using the Phaser program (McCoy et al., 2005) . The model was refi ned to 2.25 Å using alternate cycles of REFMAC5 (Vagin et al., 2004) and COOT (Emsley and Cowtan, 2004) . The quality of the resultant models was analyzed using MolProbity (Chen et al., 2010) . The crystal structure coordinates of MycP1 24-422 and MycP1 have been deposited in the PDB with accession codes 4KB5 and 4M1Z, respectively.
Expression, purifi cation, and cleavage assay of recombinant EspB
The DNA sequence encoding full-length EspB was amplified using PCR from a gene library of M. tuberculosis and inserted into the pET22b vector (Novagen) to include an N-terminally fused hexahistidine-MBP tag. The construct was transformed into E. coli BL21 (DE3) (Stratagene) for protein expression. Cells were grown in LB medium at 37°C until the OD 600 reached 0.8, then protein production was induced using 0.5 mmol/L IPTG at 37°C for 4 h. The hexahistidine-MBP-tagged protein was purifi ed by affi nity chromatography using a Ni-NTA column (Qiagen). The hexahistidine-MBP tag was cleaved by incubation with PreScission protease, and the tag-free protein was further purifi ed by size-exclusion chromatography using a HiLoad 16/60 Superdex 200 GL (GE Healthcare). The purifi ed EspB protein was analyzed using SDS-PAGE. The EspB cleavage assay was performed in reaction buffer containing 20 mmol/L MES pH 6.0 and 100 mmol/L NaCl. EspB (10 μmol/L) was digested with wild-type MycP1 , MycP1
63-422 or proteolytically inactive MycP1 at an enzyme/substrate molar ratio of 1:5 at 37°C. Samples were taken at the indicated time points, and the reactions were stopped by the addition of SDS-PAGE loading buffer and subsequent boiling. Degraded EspB products were analyzed using SDS-PAGE and visualized using Coomassie Blue staining.
Molecular dynamics simulations
The crystal structures of MycP1 24-422 and MycP1 63-422 were used to prepare molecular dynamic simulations. The two proteins were simulated under the same conditions using GROMACS-4.5.4 (Van Der Spoel et al., 2005) and the amber99SB-ILDN force fi eld. The model was initially energetically minimized to remove geometric strain. The energy-minimized model was hydrated using the TIP3P water model and a dodecahedron box. Energy minimization was performed using a steepest descent approach, with the convergence criterion set as 1 kJ/mol•nm and a step size of 0.01 nm. Position restrained MD simulation was then carried out, with the protein position fi xed and solvent equilibrated freely. During this process, temperature was increased to 303 K by a reverse annealing process and the pressure was set to 1 bar. The equilibration was fi nished in 320 ps. MD simulations (15 ns) without position restraints were implemented, using the MD integrator and a step size of 2 fs. Mass translation of the whole system was removed every 10 steps. The Van der Waals interaction cutoff was set as 1.4 nm. RMSD, RMSF, and B-factors were calculated according to backbone Cα atoms. The whole trajectory was fi tted to the start frame.
